Affiliation:
1. Department of Nervous Diseases and Neurosurgery, Sklifosovsky Emergency Institute, FSAEI HVE First Moscow State Medical University named after Sechenov I.M. (Sechenov University)
Abstract
Nowadays, the novel coronavirus infection (COVID-19) pandemic is one of the most important global health problems. There is increasing evidence that COVID-19 affects central and peripheral nervous system as well. The paper presents a clinical case of a 47 old patient with the ApoE ε4 haplotype and family history of Alzheimer’s disease who developed cognitive impairment after acute COVID-19. Before the infection the patient has no cognitive complaints and preserved everyday activity. After novel coronavirus infection, which was observed in mild form, the patient had started to complain on constant excessive forgetfulness. Neuropsychological assessment confirmed the presence of pre-mild cognitive impairment of predominantly single domain amnestic type. However, brain MRI showed only subtle periventricular white matter changes usually attributed to small vessel disease. Memory complaints were observed for 3 months of follow up despite intensive cognitive training, optimization of lifestyle and therapy with choline alphoscerate. Probable links between coronavirus infectious and cognitive impairment manifestation are discussed. There is data that ApoE ε4 haplotype is associated with increase of microglia mediated neuro-inflammation and it can be significant for accelerating of progression of neurodegenerative diseases after COVID-19. Further follow up of the patient is necessary for determination of nosological diagnosis explaining manifested predominantly amnestic type pre-mild cognitive impairment.
Publisher
Medical Informational Agency Publishers
Subject
Psychiatry and Mental health,Clinical Neurology,Neurology
Reference17 articles.
1. Chan J., Oo S., Chor C.Y.T., Yim D., Chan J.S.K., Harky A. COVID-19 and literature evidence: should we publish anything and everything? Acta Biomed. 2020;91(3):e2020020. DOI: 10.23750/abm.v91i3.9827. PMID: 32921717; PMCID: PMC7717020.
2. Baig A.M., Sanders E.C. Potential neuroinvasive pathways of SARS-CoV-2: Deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19). J Med Virol. 2020;92(10):1845–1857. DOI: 10.1002/jmv.26105
3. Paliwal V.K., Garg R.K., Gupta A., Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci. 2020;41(11):3039–3056. DOI: 10.1007/s10072-020-04708-8. Epub 2020 Sep 15. PMID: 32935156; PMCID: PMC7491599.
4. Sun T., Guan J. Novel coronavirus and the central nervous system. Eur J Neurol. 2020;27(9):e52. DOI: 10.1111/ene.14227. Epub 2020 Apr 24. PMID: 32216009.
5. Chen X., Laurent S., Onur O.A., Kleineberg N.N., Fink G.R., Schweitzer F., Warnke C. A systematic review of neurological symptoms and complications of COVID-19. J Neurol. 2020; Jul 20:1–11. DOI: 10.1007/s00415-020-10067-3. Epub ahead of print. PMID: 32691236; PMCID: PMC7370630.